IQVIA (NYSE:IQV) Rating Increased to Buy at Wall Street Zen

IQVIA (NYSE:IQV) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday.

IQV has been the subject of several other research reports. HSBC set a $210.00 price objective on IQVIA in a report on Wednesday, June 3rd. Morgan Stanley set a $225.00 price objective on IQVIA in a research report on Thursday, May 7th. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research report on Friday, March 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $224.13.

IQVIA Trading Up 0.0%

Shares of IQV stock opened at $181.10 on Friday. The company has a market cap of $30.23 billion, a P/E ratio of 22.44, a PEG ratio of 1.56 and a beta of 1.21. The stock has a 50 day simple moving average of $173.56 and a two-hundred day simple moving average of $193.68. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA has a fifty-two week low of $153.01 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts forecast that IQVIA will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of IQV. Brighton Jones LLC boosted its holdings in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC boosted its holdings in IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after acquiring an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new stake in IQVIA in the 2nd quarter worth approximately $514,000. First Trust Advisors LP lifted its holdings in IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.